Home > Zyngenia Salary

Zyngenia Salary

  • 31
  • 79
  • 100
Zyngenia average salary is $55,400, median salary is $55,400 with a salary range from $55,400 to $55,400.
Zyngenia salaries are collected from government agencies and companies. Each salary is associated with a real job position. Zyngenia salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
55,400
Average
55,400
Median
55,400
High
55,400
Total 1 Zyngenia Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Accountant 55,400-55,400 Jersey City, NJ, 07097 2013 Zyngenia Accountant Salaries (1)
Zyngenia Jersey City, NJ Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Zyngenia salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Zyngenia Jobs
See more Zyngenia Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Zyngenia... Information
  • Zyngenia Inc
  • Industry: BioTech/Drugs
  • City: Gaithersburg, MD
  • At Zyngenia, we are developing the next generation of antibody-based drugs called Zybodies?. We are spearheading the development of this novel class of drugs to create more potent and more broadly acting protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.Zybodies? are designed to incorporate the traditional attributes of monoclonal antibodies (mAbs) such as stability, ease of production, half-life, and effector function, into a single antibody-like protein that is able to interact with multiple targets. This multi-specificity of Zybodies? enables them to recognize two, three, or four different antigens concomitantly (termed ¡°single protein-combination therapy¡±) and it is